Combined technology solution evaluates study data within the EDC system against contract criteria and generates financial transactions and all related accounting information
Clinverse, Inc.
, a global technology and eclinical commerce network for clinical trials, announced today it has formed a strategic partnership with
OmniComm Systems, Inc.
, a provider of EDC solutions.
Clinverse’s ClinPay solution automates sponsor payments to clinical vendors, investigators, and other parties throughout the entire financial lifecycle of a clinical trial. OmniComm’s TrialMaster EDC suite automates data collection and data validation and offers the unique capabilities of centralized monitoring with auto-redaction and automated SDTM export utility, allowing for efficient and cost-effective trial management.
Together with ClinPay, the combined solution automatically evaluates study data within the EDC system against contract criteria and directly generates financial transactions and all related accounting information. This combination optimizes cost savings by streamlining an inherently error-prone manual process and substantially reduces labor costs associated with the payment and accounting process for clinical vendors and investigative sites.
“We are pleased to be in a strategic partnership with such an innovative and forward-thinking EDC provider as OmniComm,” said Steve Ayala, Clinverse President and head of strategic partnerships. “OmniComm’s global footprint expands Clinverse’s reach to a broader international audience of pharmaceutical and biotech companies, CROs, research, and medical device organizations that can greatly benefit from automated payment capabilities in conjunction with their EDC services.”
Clinverse’s open application programming interface (API) allows for seamless integration with existing systems, such as OmniComm’s TrialMaster suite, as well as other external eclinical data sources, such as CTMS, IxRS, ERP systems, and data warehouses. When integrated with OmniComm’s TrialMaster EDC, sponsors and/or CROs are assured that accurate and direct financial transaction data feeds are automatically routed through the appropriate channels resulting in consistent and timely payments, whether by procedure,visit or any other contracted term.
“Most of the clinical sites we work with are required to use multiple EDC systems for various studies. Two of their biggest frustrations are the lack of intuitiveness of most EDC systems and the need for accurate and timely study payments,” stated Kuno van der Post, SVP of Business Development, OmniComm Systems, Inc. “Partnering with Clinverse and offering our TrialMaster EDC alongside their ClinPay solution allows us to make an exceptionally positive impact at the sites by addressing both of these key concerns.”
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.